Astellas Pharma EBIT

Astellas Pharma (ALPMF) currently reports a EBIT of $420B as of June 2026. That compares with $270B in the prior-year period — up 55.4% year over year. That is above the Healthcare sector average of $130B. Use the charts on this page to explore Astellas Pharma's EBIT history and peer comparisons.

Astellas Pharma's EBIT increased from $270B to $420B — a 55.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Astellas Pharma's EBIT of $420B is higher than the Healthcare sector average of $130B. That is roughly 214.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Astellas Pharma reported $420B in EBIT as of June 2026. That compares with $270B in the prior-year period — up 55.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $420B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for Astellas Pharma, and consider following ALPMF for alerts when major investors trade the stock.